The basal transcription machinery as a target for cancer therapy

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Villicaña, Claudia ^a   Cruz, Grisel ^a   Zurita, Mario ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cancer therapy; Gene expression; RNA polymerase; Transcription inhibition

Indexed keywords

ADENOSINE DERIVATIVE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE; DNA DIRECTED RNA POLYMERASE; FLAVOPIRIDOL; GENERAL TRANSCRIPTION FACTOR; HYPERICIN; ISOQUINOLINE; MOLECULAR THERAPY AGENT; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; RIBOSOME RNA; RNA POLYMERASE; ROTTLERIN; TRIPTOLIDE; WOGONIN;

CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL SURVIVAL; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; REVIEW; RNA TRANSCRIPTION; SENSITIZATION; TRANSCRIPTION TERMINATION; TUMOR CELL; TUMOR GROWTH;

EID: 84896739940     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-18     Document Type: Review

References (115)

1. Bywater MJ, Pearson RB, McArthur GA, Hannan RD. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nature Reviews in Cancer 2013, 13(5):299-314.
2. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009, 1(4):280-291. 10.1039/b907567d, 2752884, 20046924.
3. Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, Huser N, Proffitt C, Bliesath J, Haddach M, Schwaebe MK, Ryckman DM, Rice WG, Schmitt C, Lowe SW, Johnstone RW, Pearson RB, McArthur GA, Hannan RD. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012, 22(1):51-65. 10.1016/j.ccr.2012.05.019, 3749732, 22789538.
4. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997, 17(12):7306-7316. 232587, 9372962.
5. Radhakrishnan SK, Gartel AL. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 2006, 66(6):3264-3270. 10.1158/0008-5472.CAN-05-3940, 16540679.
6. Cho EC, Mitton B, Sakamoto KM. CREB and leukemogenesis. Crit Rev Oncog 2011, 16(1-2):37-46. 3243968, 22150306.
7. Grummt I. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. Genes Dev 2003, 17(14):1691-1702. 10.1101/gad.1098503R, 12865296.
8. Drygin D, Rice WG, Grummt I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 2010, 50:131-156. 10.1146/annurev.pharmtox.010909.105844, 20055700.
9. Nikolov DB, Burley SK. RNA polymerase II transcription initiation: a structural view. Proc Natl Acad Sci U S A 1997, 9(1):15-22.
10. Thomas MC, Chiang CM. The general transcription machinery and general cofactors. Crit Rev Biochem Mol Bio 2006, 41(3):105-178.
11. Huisinga KL, Pugh BF. A genome-wide housekeeping role for TFIID and a highly regulated stress-related role for SAGA in Saccharomyces cerevisiae. Mol Cell 2004, 13(4):573-585. 10.1016/S1097-2765(04)00087-5, 14992726.
12. Rodríguez-Navarro S. Insights into SAGA function during gene expression. EMBO Rep 2009, 10(8):843-850. 10.1038/embor.2009.168, 2726681, 19609321.
13. Spedale G, Timmers HT, Pijnappel WW. ATAC-king the complexity of SAGA during evolution. Genes Dev 2012, 26(6):527-541. 10.1101/gad.184705.111, 3315114, 22426530.
14. Egly JM, Coin F. A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair factor. DNA Repair 2011, 10(7):714-721. 10.1016/j.dnarep.2011.04.021, 21592869.
15. Akhtar MS, Heidemann M, Tietjen JR, Zhang DW, Chapman RD, Eick D, Ansari AZ. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Mol Cell 2009, 34:387-393. 10.1016/j.molcel.2009.04.016, 2757088, 19450536.
16. Mittler G, Kremmer E, Timmers HT, Meisterernst M. Novel critical role of a human Mediator complex for basal RNA polymerase II transcription. EMBO Rep 2001, 2(9):808-813. 10.1093/embo-reports/kve186, 1084041, 11559591.
17. Conaway RC, Conaway JW. Origins and activity of the Mediator complex. Semin. Cell Dev Biol 2011, 22(7):729-734. 10.1016/j.semcdb.2011.07.021, 3207015, 21821140.
18. Hengartner CJ, Myer VE, Liao SM, Wilson CJ, Koh SS, Young RA. Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases. Mol Cell 1998, 2(1):43-53. 10.1016/S1097-2765(00)80112-4, 9702190.
19. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by CDK8-containing mediator complexes. Nature 2000, 407(6800):102-106. 10.1038/35024111, 10993082.
20. Peng J, Liu M, Marion J, Zhu Y, Price DH. RNA polymerase II elongation control. Cold Spring Harb Symp Quant Biol 1998, 63:365-370. 10.1101/sqb.1998.63.365, 10384301.
21. Fu TJ, Peng J, Lee G, Price DH, Flores O. Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. J Biol Chem 1999, 274(49):34527-34530. 10.1074/jbc.274.49.34527, 10574912.
22. Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev 2011, 25(7):661-672. 10.1101/gad.2015411, 3070929, 21460034.
23. Luo Z, Lin C, Shilatifard A. The super elongation complex (SEC) family in transcriptional control. Nat Rev Mol Cell Biol 2012, 13(13):543-547.
24. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007, 282(18):13141-13145. 10.1074/jbc.R700001200, 17329240.
25. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ, Singer DS. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A 2012, 109(18):6927-6932. 10.1073/pnas.1120422109, 3345009, 22509028.
26. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mo Cell Biol 2005, 6(8):635-645.
27. Cabarcas S, Schramm L. RNA polymerase III transcription in cancer: the BRF2 connection. Molecular Cancer 2011, 10:47. doi: 10.1186/1476-4598-10-47, 3098206, 21518452.
28. Derenzini M, Montanaro L, Treré D. What nucleolus says to a tumor pathologist. Histopathology 2009, 54(6):753-762. 10.1111/j.1365-2559.2008.03168.x, 19178588.
29. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151(1):56-67. 10.1016/j.cell.2012.08.026, 3462372, 23021215.
30. Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S, Marshall S, Florens L, Washburn MP, Shilatifard A. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol Cell Biol 2012, 32(13):2608-2617. 10.1128/MCB.00182-12, 3434493, 22547686.
31. Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT, Lee JT. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 2013, 152(4):727-742. 10.1016/j.cell.2013.01.034, 3875356, 23415223.
32. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist S. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012, 150(3):549-562. 10.1016/j.cell.2012.06.031, 3438889, 22863008.
33. Bensaude O. Inhibiting eukaryotic transcription: which compound to choose? How to evaluate its activity?. Transcription 2011, 2(3):103-108. 10.4161/trns.2.3.16172, 3173647, 21922053.
34. Stellrecht CM, Chen LS. Transcription inhibition as a therapeutic target for cancer. Cancers 2011, 3(4):4170-4190. 10.3390/cancers3044170, 3763417, 24213132.
35. Rickert P, Corden JL, Lees E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinc CTD kinases. Oncogene 1999, 18(4):1093-1102. 10.1038/sj.onc.1202399, 10023686.
36. Dubois MF, Nguyen VT, Bellier S, Bensaude O. Inhibitors of transcription such as 5,6-Dichloro-l-β-D-ribofuranosylbenzimidazole and isoquinolinesulfonamide derivatives (H-8 and H-7*) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit. J Biol Chem 1994, 269(18):13331-13336.
37. Kumahara E. Immediate-early genes zif268 and c-fos by a mechanism unrelated to inhibition of protein kinase C but possibly related to inhibition of phosphorylaton of RNA polymerase II. J Biol Chem 1998, 274(15):10430-10438.
38. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Chen Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, Kolinsky K, Felix B, Hussain S, Heimbrook D. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006, 5(11):2644-2658. 10.1158/1535-7163.MCT-06-0355, 17121911.
39. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011, 11(3):377-383. 10.1016/j.intimp.2011.01.012, 21255694.
40. Tuniretto V, Porcedda P, Orlando L, De Marchi M, Amoroso A, Giachino C. The cyclin-dependent kinase inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status. BMC Cancer 2009, ?. doi:10.1186/1471-2407-9-281.
41. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, Totzke F, Schächtele C, Lerman AS, Carnero A, Wan Y, Gray Meijer N. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005, 280(35):31208-31219. 10.1074/jbc.M500806200, 15975926.
42. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001, 60(4):785-789.
43. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D, Wong LS, Green S, Chiao J, Cui CY, Lai YF, Lee SC, Mow B, Soong R, Salto-Tellez M, Goh BC. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator in undifferentiated nasopharyngeal cancer. Clin. Cancer Res. 2009, 15(4):1435-1442. 10.1158/1078-0432.CCR-08-1748, 19228744.
44. Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL. ARS (NSC 188491) has identical activity to sangivamycin (NSC65346) including inhibition of both P-TEFb and PKC. BMC Cancer 2009, ?. doi:10.1186/1471-2407-9-63.
45. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is the next?. Trends Pharmacol Sci 2008, 29(1):16-21. 10.1016/j.tips.2007.10.012, 18054800.
46. Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Köhler R, Giaisi M, Efferth T, Desaubry L, Krammer PH, Li-Weber M. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis 2011, 2:e182. doi: 10.1038/cddis.2011.66, 10.1038/cddis.2011.66, 3199715, 21776020.
47. Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared with flavopiridol. Int J Cancer 2012, 130(5):1216-1226. 10.1002/ijc.26127, 21484792.
48. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001, 276:31793-31799. 10.1074/jbc.M102306200, 11431468.
49. Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology 2011, 22(9):2137-2143. 10.1093/annonc/mdq734, 21325451.
50. Zheleva A, Tolekova A, Zhelev M, Uzunova V, Platikanova M, Gadzheva V. Free radical reactions might contribute to severe alpha amanitin hepatotoxicity-A hypothesis. Med Hypotheses 2007, 69(2):361-367. 10.1016/j.mehy.2006.10.066, 17336461.
51. Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Morimatsu M, Fukushima M, Yamasaki Y, Inanami O. A nucleoside anticancer drug, 1-(3-C- ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS-106), sensitizes cells to radiation by suppressing BRCA2 expression. Molecular Cancer 2011, ?. doi:10.1186/1476-4598-10-92.
52. Friday B, Lassere Y, Meyers CA, Mita A, Abbruzzese JL, Thomas MB. A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. Anticancer Res 2012, 32(5):1689-1696.
53. Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y, Smeaton M, Demain AL, Miller PS, Kugel JF, Goodrich JA, Liu JO. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011, 7(3):182-188. 10.1038/nchembio.522, 3622543, 21278739.
54. Nonnekens J, Perez-Fernandez J, Theil AF, Gadal O, Bonnart C, Giglia-Mari G. Mutations in TFIIH causing trichothiodystrophy are responsible for defects in ribosomal RNA production and processing. Hum Mol Genet 2013, 22(14):2881-2893. 10.1093/hmg/ddt143, 23562818.
55. Soundararajan R, Sayat R, Robertson GS, Marignani PA. Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biol Ther 2009, 8(21):2054-2062. 10.4161/cbt.8.21.9803, 19783906.
56. Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Laiho MA. Targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 2014, 13(1):77-90.
57. Alekseev S, Ayadi M, Brino L, Egly JM, Larsen AK, Coin F. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum. Chem Biol 2014, ?. doi:10.1016/j.chembiol.2013.12.014. [Epub ahead of print].
58. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. Nature 2010, 468(7327):1067-1073. 10.1038/nature09504, 3010259, 20871596.
59. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146(6):904-917. 10.1016/j.cell.2011.08.017, 3187920, 21889194.
60. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478(7370):524-528. 10.1038/nature10334, 3328300, 21814200.
61. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A 2011, 109(47):19408-19413.
62. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478(7370):529-533. 10.1038/nature10509, 3679520, 21964340.
63. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153(2):320-344. 10.1016/j.cell.2013.03.036, 23582323.
64. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005, 106(9):2513-2519. 1895272, 15972445.
65. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. Risk factors for tumorlysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 2011, 25(9):1444-1451. 10.1038/leu.2011.109, 3162125, 21606960.
66. Yankulov K, Yamashita K, Roy R, Egly JM, Bentley DL. Inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J Biol Chem 1995, 270(41):23922-23925. 10.1074/jbc.270.41.23922, 7592583.
67. Shima D, Yugami M, Tatsuno M, Wada T, Yamaguchi Y, Handa H. Mechanism of H-8 inhibition of cyclin-dependent kinase 9: study using inhibitor-inmobilized matrices. Genes to Cells 2003, 8(3):215-223. 10.1046/j.1365-2443.2003.00627.x, 12622719.
68. Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D. Crystal structure of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesylfonyl protein kinase inhibitors H7, H8 and H89. J Biol Chem 1996, 271(42):26157-26164. 10.1074/jbc.271.42.26157, 8824261.
69. Khattar V, Thottassery JV. Cks1: structure, emerging roles and implications in multiple cancers. J Cancer Ther 2013, 4(8):1341-1354. 10.4236/jct.2013.48159, 3930463, 24563807.
70. Ali MA, Choy H, Habib AA, Saha D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 2007, 9(5):370-381. 10.1593/neo.07136, 1877978, 17534442.
71. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999, 59(21):5433-5437.
72. Cho SJ, Kim YJ, Surh YJ, Kim BM, Lee SK. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem 2011, 286(22):19662-19671. 10.1074/jbc.M110.209551, 3103345, 21478145.
73. Morachis JM, Huang R, Emerson BM. Identification of kinase inhibitors that target transcription initiation by RNA polymerase II. Oncotarget 2011, 1-2:18-28.
74. de Witte P, Gostinis P, Van Lint J, Merlevede W, Vandenheede JR. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin. Biochem Pharmacol 1993, 46(11):1929-1936. 10.1016/0006-2952(93)90633-8, 8267642.
75. Lavie G, Meruelo D, Aroyo K, Mandel M. Inhibition of the CD8+ T cell-mediated cytotoxic reaction by hipericin: potential for treatment of T cell-mediated diseases. Int Immunol 2000, 12(4):479-486. 10.1093/intimm/12.4.479, 10744649.
76. Davies SP, Reddy H, Caivano M, Cohen. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem 2000, 351(1):95-105.
77. Bennett BL, Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci 2001, 98(4):13682-13686.
78. Shimamoto Y, Fujioka A, Kazuno H, Murakami Y, Ohshimo H, Kato T, Matsuda A, Sasaki T, Fukushima M. Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl) cytosine. Cancer Res 2001, 92(3):343-351.
79. Yasui H, Ogura A, Asanuma T, Matsuda A, Kashiwakura I, Kuwabara M, Inanami O. Inhibition of HIF-1α by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. Br J Cancer 2008, 99(9):1442-1452. 10.1038/sj.bjc.6604720, 2579694, 18854835.
80. Iben S, Tschochner H, Bier M, Hoogstraten D, Hozák P, Egly JM, Grummt I. TFIIH plays an essential role in RNA polymerase I transcription. Cell 2002, 109(3):297-306. 10.1016/S0092-8674(02)00729-8, 12015980.
81. Assfalg R, Lebedev A, Gonzalez OG, Schelling A, Koch S, Iben S. TFIIH is an elongation factor of RNA polymerase I. Nucleic Acids Res 2011, 40(2):1-10. 3245913, 21908400.
82. Manzo SG, Zhou ZL, Wang YQ, Marinello J, He JX, Li YC, Ding J, Capranico G, Miao ZH. Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Res 2012, 72(20):5363-5373. 10.1158/0008-5472.CAN-12-1006, 22926559.
83. Vispé S, DeVries L, Créancier L, Besse J, Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, Guilbaud N, Barret JM, Bailly C. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009, 8(10):2780-2790. 10.1158/1535-7163.MCT-09-0549, 19808979.
84. Villicaña C, Cruz G, Zurita M. The genetic depletion or the triptolide inhibition of TFIIH in p53 deficient cells induce a JNK-dependent cell death in Drosophila. J Cell Sci 2013, 126(11):2502-2515. 10.1242/jcs.122721, 23549790.
85. Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, Streiner N, Quin JE, Sanij E, Bywater MJ, Hannan RD, Ryckman D, Anderes K, Rice WG. CX-5461 Inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 2011, 71(4):1418-1430. 10.1158/0008-5472.CAN-10-1728, 21159662.
86. Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Näär AM, Dyson NJ. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008, 455(7212):552-556. 10.1038/nature07310, 3148807, 18794899.
87. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010, 24(8):837-852. 10.1101/gad.1897010, 2854397, 20395368.
88. Okuyama H, Endo H, Akashika T, Kato K, Inoue M. Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010, 70(24):10213-10223. 10.1158/0008-5472.CAN-10-2720, 20980433.
89. Whitessell L, Lindquist S. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets 2009, 13(4):469-478. 10.1517/14728220902832697, 19335068.
90. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 2010, 24(12):2267-2280. 10.1210/me.2010-0238, 2999477, 20980437.
91. Kaichi S, Takaya T, Morimoto T, Sunagawa Y, Kawamura T, Ono K, Shimatsu A, Baba S, Heike T, Nakahata T, Hasegawa K. Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes. J Cell Physiol 2011, 226(12):248-254.
92. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM, Firestein R. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res 2012, 72(8):2129-2139. 10.1158/0008-5472.CAN-11-3886, 22345154.
93. Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukaemia (AML). Oncotarget 2012, 3(12):1588-1599. 3681497, 23249862.
94. Derheimer FA, Chang CW, Ljungman M. Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer 2005, 41(16):2569-2576. 10.1016/j.ejca.2005.08.012, 16213135.
95. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001, 2:research0041.0041-research0041.0011.
96. Gutiérrez L, Merino C, Vázquez M, Reynaud E, Zurita M. RNA polymerase II 140wimp mutant and mutations in the TFIIH subunit XPB differentially affect homeotic gene expression in Drosophila. Genesis 2004, 40(1):58-66. 10.1002/gene.20066, 15354295.
97. Merino CE, Reynaud M, Vazquez M, Zurita M. DNA repair and transcriptional effects on mutations in TFIIH in Drosophila development. Mol Biol Cell 2002, 13(19):3246-3256. 124156, 12221129.
98. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004, 45(2):373-376. 10.1080/1042819031000139710, 15101726.
99. Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, Lu D, Cheng EH, Hsieh JJ. Taspase 1 function as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Res 2010, 70(13):15358-15367.
100. Gabai VL, Meng L, Kim G, Mills TA, Benjamin IJ, Sherman MY. Heat shock transcription factor HSF1 is envolved in tumor progresión via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. Mol Cell Biol 2012, 32(5):929-940. 10.1128/MCB.05921-11, 3295200, 22215620.
101. Dai C, Meng L, Kim G, Mills TA, Benjamin IJ, Sherman MY. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130(6):1005-1018. 10.1016/j.cell.2007.07.020, 2586609, 17889646.
102. Phillips DA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, Saluja AK. Triptolide induces pancreatic cancer cell death via inhibition of the heat shock protein 70. Cancer Res 2007, 67(19):9407-9416. 10.1158/0008-5472.CAN-07-1077, 17909050.
103. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153(2):307-319. 10.1016/j.cell.2013.03.035, 23582322.
104. Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier CC, Goossens J, Rahl PB, Levine SS, Taatjes DJ, Dekker J, Young RA. Mediator and cohesin connect gene expression and chromatin architecture. Nature 2010, 467(7314):430-435. 10.1038/nature09380, 2953795, 20720539.
105. Huang W, He T, Chai C, Yang Y, Zheng Y, Zhou P, Qiao X, Zhang B, Liu Z, Wang J, Shi C, Lei L, Gao K, Li H, Zhong S, Yao L, Huang ME, Lei M. Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One 2012, 7(5):e37693. 10.1371/journal.pone.0037693, 3364364, 22666381.
106. Poele RH, Okorokov AL, Joel SP. RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 1999, 18(42):5765-5772. 10.1038/sj.onc.1202961, 10523857.
107. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry 2000, 65(1):95-106.
108. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120(14):2843-2852. 10.1182/blood-2012-02-413021, 3466965, 22904298.
109. Slatter TL, Ganesan P, Holzhauer C, Mehta R, Rubio C, Williams G, Wilson M, Royds JA, Baird MA, Braithwaite AW. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death and Differentiation 2010, 17(3):540-550. 10.1038/cdd.2009.136, 19779492.
110. Tron VA, Trotter MJ, Tang L, Krajewska M, Reed JC, Ho VC, Li G. p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol 1998, 153(2):579-585. 10.1016/S0002-9440(10)65600-3, 1852971, 9708817.
111. Zhu LJ, Yan WX, Chen ZW, Chen Y, Chen D, Zhang TH, Liao GQ. Disruption of mediator complex subunit 19 (Med19) inhibits cell growth and migration in tongue cancer. World J Surg Oncol 2013, 11:116. 10.1186/1477-7819-11-116, 3673833, 23705783.
112. Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LFA, Bernards R. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 2012, 151(5):937-950. 10.1016/j.cell.2012.10.035, 3672971, 23178117.
113. Ito S, Tan LJ, Andoh D, Narita T, Seki M, Hirano Y, Narita K, Kuraoka I, Hiraoka Y, Tanaka K. MMXD, a TFIIH-independent XPD-MMS19 protein complex involved in chromosome segregation. Mol Cell 2010, 39(4):632-640. 10.1016/j.molcel.2010.07.029, 20797633.
114. Weber A, Chung H, Springer E, Heitzmenn D, Warth R. The TFIIH subunit p89 (XPB) localizes to the centrosome during mitosis. Cell Oncol 2010, 32(1-2):121-130.
115. You J, Li Q, Wu C, Kim J, Ottinger M, Howley PM. Regulation of Aurora B expression by the bromodomain protein Brd4. Mol Cell Biol 2009, 29(18):5094-5103. 10.1128/MCB.00299-09, 2738288, 19596781.